| 中文名称 | 盐酸阿柔比星 |
| 英文名称 | ACLARUBICIN HYDROCHLORIDE |
| CAS号 | 75443-99-1 |
| 分子式 | C42H54ClNO15 |
| 分子量 | 848.33 |
| EINECS号 | 278-209-3 |
| 熔点 | 151-153℃ |
| 沸点 | 898℃ |
| 闪点 | >110°(230°F) |
| 溶解度 | 溶于DMSO或DMF,浓度为25mg/ml |
| 形态 | 固体 |
| 颜色 | 浅黄至黄色 |
| 危险品标志 | T |
| 危险类别码 | 23/24/25 |
| 安全说明 | 36/37/39-45 |
| 危险品运输编号 | 3249 |
| RTECS号 | QI9283500 |
| 危险等级 | 6.1(a) |
| 包装类别 | II |
20S proteasome.
Topoisomerase I and II.
Aclacinomycin A could efficiently enter living cells and emit fluorescence
in situ
. Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM Acla for 15 min) results in approximately 20% dead (or nearly dead) cells.
Aclacinomycin A (Aclarubicin) effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34 .
Aclacinomycin A is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD
50
(76.5 mg/kg) is about twice the iv LD
50
(35.6 mg/kg) in mice
[4
.
Aclacinomycin A (0.75-6 mg/kg, ip daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model
[4
.
| Animal Model: | DBA/2, CDF 1 (BALB/c×DBA/2) mice with Leukemia P-388 [4 . |
| Dosage: | 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. |
| Administration: | Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. |
| Result: | Inhibited tumor growth. |